CTRI/2016/06/006998招募中4 期
Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in treatment of patients with castration resistant prostate cancer
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients with histologically proven prostate cancer who have been treated by either surgery or radiotherapy and antiandrogen therapy
- •First line or Second line therapy for CRPC given but rising PSA
- •sPSA greater than 5ng per ml
- •Ga68 PSMA showing sites of PSMA expressing disease
- •Normal Kidney Function Test and Liver Function Test
- •Karnofsky performance status greater than 60
- •Patients with GRF level greater than 60 ml per min
排除标准
- •Negative Ga68 PSMA scan
- •Coexisting second malignancies
- •Patients with
- •Hbless than 11 gm percent
- •Platelet count less than 150000 per cumm
- •TLC less than 4000 per cumm
- •Serum Creatinine greater than 1.3 mg percent
- •Anticipated life expectancy of less than 3 months
- •Patients who refuse written informed consent
研究者
相似试验
已完成
1 期
An early phase clinical trial evaluating the effectiveness of treatment of 177Lu-PSMA with idronoxil in men with castrate-resistant prostate cancer (LuPin Trial)ACTRN12618001073291St Vincent's Hospital Sydney56
尚未招募
2 期
utetium PSMA versus docetaxel in metastatic prostate cancerCTRI/2022/03/041265All India Institute of Medical Sciences New Delhi
已完成
1 期
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPCProstate CancerNCT03042468Weill Medical College of Cornell University50
招募中
2 期
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA TrialCastration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8NCT06288113Jonsson Comprehensive Cancer Center40
已完成
不适用
RAD327 Lu-177 Dosimetry with SPECT/CTneuroendocrine tumorsC80C17C25.9Malignant neoplasm, without specification of siteMalignant neoplasm of small intestinePancreas, unspecifiedDRKS00011489niversitätsklinikum Magdeburg6